MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.

Panda, Mamta; Kalita, Elora; Singh, Satyendra; Kumar, Ketan; Rao, Abhishek; Prajapati, Vijay Kumar

Panda, Mamta; Kalita, Elora; Singh, Satyendra; Kumar, Ketan; Rao, Abhishek; Prajapati, Vijay Kumar.

Afiliação

Panda M; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Kalita E; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Singh S; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Kumar K; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Rao A; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.
Prajapati VK; Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India. Electronic address: vkprajapati@curaj.ac.in.

Life Sci ; 305: 120761, 2022 Sep 15.

Article em En | MEDLINE | ID: mdl-35787998

Assuntos

COVID-19; MicroRNAs; Humanos; MicroRNAs/genética; MicroRNAs/metabolismo; SARS-CoV-2

Palavras-chave

Biomarker; MiRNA; Pathogen-host interaction; RNA silencing; SARS coronavirus 2

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Life Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Índia País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google